Pharmacy chain Walgreens Boots Alliance and other defendants on April 26 said they were not to blame for the opioid crisis in San Francisco, and that they acted responsibly when providing legal medications to patients in pain.
San Francisco squared off on April 25 against Walgreens Boots Alliance and three other companies accused of fueling an opioid crisis in the city, the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines.
McKinsey & Company, a consulting firm that covers multiple industries including healthcare and life sciences, is under fire for allegedly allowing its employees to work simultaneously for big pharma companies and serve as consultants for the U.S. Food and Drug Administration.
Rhode Island was set to square off on March 14 against Teva Pharmaceutical Industries Ltd., as a multibillion-dollar trial begins over whether the Israeli company contributed to an opioid crisis that has caused more than 500,000 deaths over the past two decades.
One day after U.S. bankruptcy judge Robert Drain approved an opioid settlement plan that locks Purdue Pharma’s Sackler family into paying about $6 billion into the nationwide fund, family members of those whose lives were devastated by addiction to drugs like OxyContin confronted the de facto face of the nation’s opioid crisis in court.
The Sackler family owners of Purdue Pharma LP reached a deal with nine state attorneys general to pay up to $6 billion in cash to resolve widespread litigation alleging that they fueled the U.S. opioid epidemic, bringing the OxyContin maker closer to exiting bankruptcy.
A mediator in Purdue Pharma’s bankruptcy case on March 2 indicated an agreement was being drafted between the company’s owners and U.S. states pressing for more money to resolve allegations that the OxyContin maker fueled the opioid epidemic.
The U.S. Food and Drug Administration approved the use of Purdue Pharma’s candidate injectable treatment for partially or completely reversing opioid drug effects.
The Sackler family owners of Purdue Pharma LP proposed a new and larger settlement worth up to $6 billion to resolve allegations that the OxyContin maker and the company’s owners contributed to the deadly U.S. opioid epidemic, a mediator’s report showed on February 18.
A federal judge on Feb. 1 extended a legal shield protecting the Sackler family owners of Purdue Pharma from lawsuits to Feb. 17, as they try to reach a deal with several states to settle sprawling litigation stemming from the U.S. opioid crisis.